Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial.

Lung · 2025 · PMC12041137 · PMID 40299084

Europe PMC DOI

hedged sentence

0.3700

closest p · 7.4× alpha

0.3700

boldest claim

The sentences

did not reach statistical significancep = 0.370not close (p > 0.1)

Among those with severe reflux symptoms, LCQ score improvements were numerically greater in the fexuprazan group than in the esomeprazole group, but the difference did not reach statistical significance (n = 15; 8.3 ± 2.8 vs. 6.7 ± 1.7, p = 0.370).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.